Search
forLearn
5 / 801 resultslearn plant sterol complex
learn Baicapil
learn Pump BioGro™️
learn Isopropylmethylphenol
Research
5 / 411 results
research Intestinal Permeability Study of Minoxidil: Assessment of Minoxidil as a High Permeability Reference Drug for Biopharmaceutics Classification
Minoxidil works well as a high permeability reference drug for biopharmaceutics classification.
research The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil
Minoxidil's absorption is too variable for it to be a reliable reference drug.
research Absorption sites of orally administered drugs in the small intestine
Different factors affect where drugs are absorbed in the small intestine, which is important for effective medication use.
research Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Solid lipid nanoparticles are promising for safe and effective drug delivery but need more research for clinical use.
research Research Progress of Platelet-Rich Plasma in the Treatment of Discogenic Low Back Pain
Platelet-Rich Plasma shows promise for treating low back pain but needs more research.
Community Join
5 / 1000+ resultscommunity HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days!
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.